Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

This promotional webcast series has been developed, organised and funded by Novo Nordisk for UK healthcare professionals only.

Novo Nordisk product information will be discussed.
Prescribing information for OZEMPIC®▼ (semaglutide), RYBELSUS®▼ (semaglutide tablets) & VICTOZA® (liraglutide) and adverse events reporting can be found at the bottom of this page.

fORward thinking in type 2 diabetes: Optimising adult care to improve outcomes

A series of five interactive webcasts
for healthcare professionals

July to November 2021

Novo Nordisk
Diabetes Network webcast series

Providing optimal care for people with type 2 diabetes is a long-term endeavour; with time, patients’ glycaemic control and cardiovascular risk can change, so regular review and early treatment intensification is essential. But many factors can lead to patients living with suboptimal control of their diabetes for months or even years – especially in the current climate, when healthcare professionals may be struggling to cope with the backlog of diabetes care caused by over a year of disruption to routine appointments due to COVID-19.

This series of webcasts, presented by experts from across primary, community and secondary care, will tackle issues of managing the diabetes care backlog,  therapeutic inertia and treatment optimisation – with a particular focus on the GLP-1 receptor agonist (GLP-1 RA) class of type 2 diabetes medication, and how these medications can be used to assist adults patients in reaching their therapeutic targets. There will also be a presentation of real-world evidence studies for specific GLP-1 RAs, a discussion of their use in adult patients with type 2 diabetes and cardiovascular disease, as well as practical case-based discussions on managing adult patients with type 2 diabetes.

Your registration allows you access to all five webcasts in the series. Once you have registered for the series, we’ll be sending you updates on the speakers and agenda for the upcoming webcasts – please keep an eye out for these updates in your email inbox over the coming weeks.

Speakers

Dr Matthew Capehorn

GP with a Special Interest in Obesity and Clinical Manager, Rotherham Institute for Obesity

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Dr Derek Connolly

Consultant Interventional Cardiologist, Sandwell and West Birmingham NHS Trust

Dr Sarah Davies

GP with a Special Interest in Diabetes & Education, Cardiff

Su Down

Nurse Consultant in Diabetes, Somerset

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Dr Patrick Holmes

GP with a Special Interest in Adult Diabetes and Obesity, Darlington

Prof Richard Holt

Professor in Diabetes and Endocrinology, University of Southampton

Dr Amrit Lamba

GP with a Special Interest in Diabetes, London

Dr Dipesh Patel

Consultant Physician in Diabetes and Endocrinology, London

Prof Ponnusamy Saravanan

Professor and Honorary Consultant Physician in Diabetes, Endocrinology and Metabolism, Warwick

Dr Adie Viljoen

Consultant Chemical Pathologist and Metabolic Physician, East and North Hertfordshire NHS Trust

What does this series offer you?

  • Five webcasts on topics that matter in everyday practice – from coping with the backlog of type 2 diabetes patient care, to confident prescribing of GLP-1 RAs
  • Expert GPs, nurses and secondary care specialists offering their insights and clinical experience
  • Q&A sessions at each live webcast broadcast, to ask your questions to our panel of speakers
  • Recordings of all webcasts available after the broadcast, for you to revisit anything you missed or want to see again

Webcasts in the series

Diabetes: Acute Backlog Challenge through COVID-19 and beyond

5 minutes

Introduction and welcome

15 minutes

Therapeutic inertia

10 minutes

Impact of COVID-19 on the backlog of patients with diabetes

15 minutes

Medication review

15 minutes

Live Q&A session

Moving fORward in adult type 2 diabetes management with GLP-1 RAs

5 minutes

Introduction and welcome

5 minutes

Burden of type 2 diabetes and treatment guidelines

5 minutes

Introduction to GLP-1 RAs

15 minutes

When to intensify with an oral GLP-1 RA

15 minutes

When to intensify with an injectable GLP-1 RA

15 minutes

Live Q&A session

Real-world evidence for GLP-1 RA therapies in adults: How could it change your type 2 diabetes practice?

5 minutes

Introduction and welcome

5 minutes

Generating real-world evidence

15 minutes

RYBELSUS®▼ (semaglutide tablets) in real-world clinical practice

20 minutes

Real-world experience of once-weekly semaglutide in type 2 diabetes

15 minutes

Live Q&A session

Type 2 diabetes and cardiovascular disease: An evidence-based discussion of
GLP-1 RAs in adults

5 minutes

Introduction and welcome

5 minutes

Background: The burden of cardiovascular disease in adults with type 2 diabetes

15 minutes

Introduction to once-weekly and oral semaglutide

20 minutes

GLP-1 RA cardiovascular outcome trials: Focus on SUSTAIN 6 and PIONEER 6

15 minutes

Live Q&A session

Helping our adult patients live well with type 2 diabetes: A case-based discussion

Details coming soon

5 minutes

Introduction and welcome

30 minutes

A case-based discussion of key topics in adult type 2 diabetes care

A discussion of three fictional patient cases exploring key facts of type 2 diabetes care, with a particular focus on the role of the GLP‑1 RA class of medications:

5 minutes

Conclusions

20 minutes

Live Q&A session

Click here for OZEMPIC®▼ (semaglutide) Prescribing information
Click here for RYBELSUS®▼ (semaglutide tablets) Prescribing information
Click here for VICTOZA® (liraglutide) Prescribing information

OZEMPIC is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
• in addition to other medicinal products for the treatment of diabetes.

RYBELSUS is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise
• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
• in combination with other medicinal products for the treatment of diabetes.

VICTOZA is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
• in addition to other medicinal products for the treatment of diabetes.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes.

Job code: UK21OZM00100 | Date of preparation: September 2021

You are leaving this site.

You are now leaving https://live.diabetesonthenet.com/novo-nordisk-diabetes-network-webcast-series.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.